MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
MoonLake Immunotherapeutics reports that its nanobody drug, sonelokimab, successfully met all clinical endpoints in a Phase 3 trial for psoriatic arthritis.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
MoonLake Immunotherapeutics has announced positive results from a late-stage Phase 3 clinical trial involving its nanobody drug, sonelokimab, which is designed to treat psoriatic arthritis. According to reporting from Fierce Biotech and Dermatology Times, the drug successfully boosted all clinical endpoints and specifically met its primary end point during the trial process. This development indicates that the treatment reached the key goals necessary for the late-stage trial to be considered successful in its evaluation of efficacy for patients suffering from this specific inflammatory condition. Coverage of the announcement has been widespread across several specialized outlets. Fierce Biotech highlights the success across all clinical endpoints, while Dermatology Times focuses on the achievement of the primary end point.
Market-oriented outlets such as marketscreener.com report that the drug met its key goals. However, FirstWord Pharma notes a contrast in reception, suggesting that while the company is touting the Phase III psoriatic arthritis data, some investors may have expected more significant results than those reported by the company. Parallel to the clinical data, MoonLake Immunotherapeutics has released its financial status for the second quarter of 2026. According to Kalkine Media, the company's Q2 2026 financial results show an increase in net loss. Despite this rise in losses, the report also indicates that the company has increased its cash reserves.
This financial context provides a backdrop for the clinical success, as the company manages the high costs associated with late-stage pharmaceutical development and trial execution while maintaining the capital necessary for future operations. Moving forward, observers will likely monitor how the company leverages these Phase 3 results in the context of its current financial position. While the clinical data for sonelokimab is positive across all tested endpoints, the market reaction described by FirstWord Pharma suggests a period of investor scrutiny. Future updates will likely center on the company's plan for regulatory submission following the successful Phase 3 trial and how the increased cash reserves mentioned by Kalkine Media will be utilized to offset the reported increase in net losses.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 97d ago.
Quick answers
What drug was tested in the Phase 3 trial?
The drug tested was sonelokimab, a nanobody developed by MoonLake Immunotherapeutics.
Did the trial meet its objectives?
Yes, coverage states the drug met its primary end point and boosted all clinical endpoints.
What was MoonLake's financial status in Q2 2026?
The company reported increased cash reserves but also an increased net loss for the second quarter of 2026.
Coverage (5)
- MoonLake's psoriatic arthritis drug meets key goals in late-stage trial marketscreener.com · 97d ago
- Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial Dermatology Times · 97d ago
- MoonLake Immunotherapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Cash Reserves Kalkine Media · 97d ago
- MoonLake touts Phase III PsA data, but investors may have wanted more FirstWord Pharma · 97d ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial Fierce Biotech · 97d ago
Topics
Related trends
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson is reportedly nearing a multibillion-dollar acquisition of eye disease biotech firm Ollin Biosciences.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.
Scientists reverse liver cell aging and cut Alzheimer’s-linked protein in half
Recent reporting highlights scientific breakthroughs targeting cellular aging, liver rejuvenation, and amyloid-beta reduction.
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical reports third-quarter 2026 results while announcing major workforce reductions and pipeline cuts to target profitability.